DAXX and pancreatic neuroendocrine tumor: In addition, in pancreatic neuroendocrine tumors, ATRX/DAXX mutations are considered prognostic biomarkers in patients with poor disease-free survival (DFS), but opposite results in advanced/metastatic patients (Wang et al., 2021), indicating that ATRX mutations at different stages may have different effects and have implications for prognostic judgment.